Nanion Technologies
20.09.2017 | CiPA CardioExcyte 96 Webinar

Cipa CardioExcyte 96 Webinar

20. Sept. 2017, 4 PM CET

Presenter: Corina Bot, Nanion Inc., USA

Title: "Cross-site comparison of myocyte phase II compounds on different iPS cardiomyocytes based on CardioExcyte 96 recordings"

In this webinar, Corina Bot will present impedance and MEA-like extracellular field potential recordings on iPS cardiomyocytes. The utilized system, the CardioExcyte 96 allows to non-invasively record the contractility and the electrophysiology of beating networks of cells. Furthermore, the long-term quantification of cell morphology change and attachment quality is recorded alongside in a real-time manner. 

Cells were obtained from Axiogenesis (Cor.4U), Cellular Dynamics International, CDI (iCell cardimyocytes2), Takara (Cellartis cardiomyocytes) and Pluriomics (Pluricytes). Phase II validation study compounds have been applied and endpoints have been investigated according to the CiPA study protocol. A subset of compound results from different sites will be presented.

The webinar is free to attend.

The following link will be activated on Sept. 20th. Click here to join the webinar on the 20th Sept.

Access Code: 988-182-093

You can also dial in from the USA using your phone.
United States (Toll Free): 1 877 309 2070  

More phone numbers
Argentina (Toll Free): 0 800 444 2385
Australia (Toll Free): 1 800 191 358
Austria (Toll Free): 0 800 080061
Bahrain (Toll Free): 800 81 305
Belarus (Toll Free): 8 820 0011 0331
Belgium (Toll Free): 0 800 78881
Brazil (Toll Free): 0 800 025 8726
Bulgaria (Toll Free): 00800 120 4413
Canada (Toll Free): 1 877 777 3281
Chile (Toll Free): 800 395 146
China (Toll Free): 4007 160008
Colombia (Toll Free): 01 800 012 9057
Czech Republic (Toll Free): 800 500453
Denmark (Toll Free): 8025 0919
Finland (Toll Free): 0 800 94473
France (Toll Free): 0 805 541 052
Germany (Toll Free): 0 800 723 5274
Greece (Toll Free): 00 800 4414 4282
Hong Kong (Toll Free): 30774812
Hungary (Toll Free): (06) 80 986 259
Iceland (Toll Free): 800 9993
India (Toll Free): 000 800 100 8227
Indonesia (Toll Free): 007 803 020 5384
Ireland (Toll Free): 1 800 818 263
Israel (Toll Free): 1 809 453 019
Italy (Toll Free): 800 792289
Japan (Toll Free): 0 120 242 200
Korea, Republic of (Toll Free): 0806180880
Luxembourg (Toll Free): 800 81016
Malaysia (Toll Free): 1 800 81 6860
Mexico (Toll Free): 01 800 112 4376
Netherlands (Toll Free): 0 800 023 1954
New Zealand (Toll Free): 0 800 47 0051
Norway (Toll Free): 800 69 055
Panama (Toll Free): 001 800 507 2789
Peru (Toll Free): 0 800 55465
Philippines (Toll Free): 1 800 1110 1669
Poland (Toll Free): 00 800 1124748
Portugal (Toll Free): 800 819 683
Romania (Toll Free): 0 800 410 025
Russian Federation (Toll Free): 8 800 100 6216
Saudi Arabia (Toll Free): 800 844 3636
Singapore (Toll Free): 800 101 3000
South Africa (Toll Free): 0 800 555 451
Spain (Toll Free): 800 900 593
Sweden (Toll Free): 0 200 330 924
Switzerland (Toll Free): 0 800 000 452
Taiwan (Toll Free): 0 800 666 846
Thailand (Toll Free): 001 800 852 2442
Turkey (Toll Free): 00 800 4488 29001
Ukraine (Toll Free): 0 800 50 1784
United Arab Emirates (Toll Free): 800 044 40444
United Kingdom (Toll Free): 0 800 389 5276
Uruguay (Toll Free): 0004 019 0670
Viet Nam (Toll Free): 122 80 106

First GoToMeeting?
Try a test session:


23. - 27.09.2017 | SPS Annual Meeting

Venue: Maritim Hotel Berlin, Germany

Niels Fertig, Sonja Stölzle-Feix, Frank Henrichsen and Elena Dragicevic are looking forward to meeting you at our booth #206.

We will present five posters in collaboration with our partners Metrion Biosciences, University Medical Center Utrecht, Cellular Dynamics and  Clontech Takara Cellartis.


"High Throughput Pharmacology of cardiac L-type Ca2+ Channels in overexpressing cell lines and iPSC-cardiomyocytes"
Download the abstract here.

"Cytotoxicity Monitoring for Safety Assessments: iPS Cardiomyocytes and Cancer Cells"
Download the abstract here.

"Differentiation and Validation of Human iPSC-Derived Atrial Cardiomyocytes"
Download the abstract here.

"Evaluation of Human iPS Cell-Derived Cardiomyocytes in High-Throughput Toxicity Screening Applications"
Download the abstract here.

"Integrating dynamic clamping with automated patch clamping devices: adding virtual IK1 channels to iPSC-CM"
Download the abstract here.

Do not miss our symposium in parallel to the SPS on Sunday 24th September, 4:00 PM - 6:30 PM  in the Maritim Hotel Salon 15 / Paris (1st floor).

Registration is free.

Title: HTS In Cardiac Safety

Eventbrite SPS Nanion Symposium Image

Find out more here.

Go to the Conference website here.

24.09.2017 | HTS in Cardiac Safety Symposium

Venue: Maritim Hotel Berlin, Germany

Niels Fertig, Sonja Stölzle-Feix, Frank Henrichsen and Elena Dragicevic are looking forward to meeting you on Sunday 24th September, 4:00 PM - 6:30 PM in the Maritim Hotel Salon 15 / Paris (1st floor).

Title: HTS In Cardiac Safety

Eventbrite SPS Nanion Symposium Image

The Symposium is free to attend.

Register here.


Confirmed speakers:

Said el Haou, Metrion Biosciences:
In depth profiling of human iPSC-CM – from electrophysiology to phenotypic assays"

Matt Burnham, AstraZeneca:
Impedance and field potential in 3D: cardiomyocyte co-culture spheroids and the CardioExcyte96 platform"
In vitro three-dimensional and co-culture cell models can provide more physiologically relevant data than conventional 2D approaches. We explored novel label-free methods to record functional data from actively beating, 3D spheroid co-cultures of iPSC cardiomyocytes. Using the Nanion CardioExcyte® 96 platform, designed for recordings from 2D iPSC cardiomyocytes monolayers, the electrical activity (extracellular field potential) and beating pattern (impedance) of cardiomyocyte spheroids could be detected. To facilitate the essential spheroid-to-electrode positioning, magnetic nano-particle based approaches were explored. Treatment with compounds known to affect beat rate and field potential duration generated appropriate results in the 3D system. A cumulative-dosing approach was developed to demonstrate a drug discovery work flow suitable for profiling studies. In comparison to a conventional contractility assay approach (2D FLIPR), significant advantages in reduced iPSC usage and cost (approximately eight-fold) and increased through-put were demonstrated. The high through-put of the system was leveraged to profile the functional phenotype of various iPSC and fibroblast co-culture types under different experimental conditions. Phenotype profiling revealed substantial differences amongst co-culture types, such as in beat amplitude and responses to E-4031. Electrical pacing revealed true inotropic responses (increased beat amplitude at constant beat rate) in some conditions. In summary, recording functional data from the 3D phenotype of spheroid co-cultures of electrically-active and beating cardiomyocytes in a screening platform has been achieved which may improve the predictivity of Safety assays and facilitate a better understanding of 3D co-culture phenotypes.

 Takasuna Kiyoshi, Daiichi Sankyo/ Novare:
Comprehensive in vitro cardiac safety assessment using human stem cell technology (CSAHi: HEART initiative) -The second stage"
1) Discovery Pharmacokinetics Research Group, Pharmaceutical and Biomedical Analysis Department, Daiichi Sankyo Rd Novare Co., Ltd.
2) Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART Team
Since 2013, we have organized the Consortium for Safety Assessment using Human iPS Cells (CSAHi; in Japan to verify the application of human iPS/ES cell-derived cardiomyocytes in drug safety evaluation. The definitive goal of the CSAHi HEART Team has been to propose comprehensive screening strategies to predict a diverse range of cardiotoxicities (arrhythmia, contractile dysfunction, and cardiomyocyte toxicity) by using recently introduced platforms (multi-electrode array [MEA], patch clamp, cellular impedance, motion field imaging [MFI], and Ca transient systems) while identifying the strengths and weaknesses of each.
Our study (the first stage) showed that hiPS-CMs used in these platforms would offer paradigm changes of platforms for predicting drug-induced QT risk and/or arrhythmia or contractile dysfunction with a greater prognostic value beyond existing indirect surrogates proposed in animal models. I will introduce the latest progress and roadmap of activities of the CSAHi HEART Team (the second stage).

Teun de Boer, University of Utrecht:
Dynamic clamping on a Patchliner: adding virtual IK1 channels to cardiomyocytes"
Department of Medical Physiology, Division Heart & Lungs, University Medical Center Utrecht. Yalelaan 50, 3584 CM Utrecht, The Netherlands
This email address is being protected from spambots. You need JavaScript enabled to view it. Abstract:
Human pluripotent stem cell-derived cardiomyocytes (hPSC-CM) are an interesting source of cells for safety pharmacology, but there are caveats that have to be taken into account. A typical property of hPSC-CM is automaticity, the cardiomyocytes beat spontaneously, resembling cells in the sinoatrial node of the heart. The spontaneous beating is due to lack of IK1 ion channels, which normally assure a stable resting membrane potential in cardiomyocytes. Work by our group has demonstrated that the depolarized state of hPSC-CM limits their usefulness in assays aimed at detecting proarrhythmic properties of drugs (Jonsson et al., 2012, PMID: 22353256).
Dynamic clamping can provide virtual, simulated IK1 channels to a real biological hPSC-CM in a patch clamping experiment. Key benefits of this approach include full control of the added IK1 conductance to each cardiomyocyte, it can be applied to any hPSC-CM source and it can be coupled to automated patch clamping machines. In this webinar I will discuss our work on using the dynamic clamping technique with a Patchliner.

28.09.2017 | iForum User Meeting

Venue: Imperial College London, UK

Elena Dragicevic is looking forward to meeting you.

Elena will give an oral presentation:

"Holistic view on state-of-the-art cardiac safety screening"
Download the abstract here.

Go to the iForum website here.

03. - 04.10.2017 | ELRIG Drug Discovery

Venue: ACC Liverpool, UK

Alison Obergrussberger is looking forward to meeting you.

Ali will present three posters:

"Newest Advances in Automated Patch Clamp: Combining flexibility with high throughput"
Download the abstract here.

"Investigations into Idiosyncratic Drug-Induced Hepatotoxicity and Chronic Proliferation of Cancer Cells using a Label-free Method"
Download the abstract here.

"Targeting transporters with HTS electrophysiology on the SURFE²R 96SE"
Download the abstract here.

Go to the Conference website here.

10. - 13.10.2017 | Biophysics Mexico

Emerging Concepts in Ion Channel Biophysics

Venue:  Old Palace of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

Andrea Brüggemann is looking forward to meeting you.

Andrea will give an oral presentation:
Tuesday, October 10, 2017, Session II: Ion Channels in Physiology, 1:55 PM - 2:15 PM.

Title: "News and Views on Cardiac Safety"

View the Conference program here.

Go to the Conference website here.

25. - 26.10.2017 | 8th Annual Nanion User Meeting Munich

Venue: Ganghoferstr. 70a, Munich, Germany


Confirmed speaker:


Thomas Licher, Sanofi Frankfurt, Germany

Lars Kästner, Saarland University, Germany

Arne Hansen, UKT Hamburg, Germany

Oliver Reinhardt, MPI for Experimental Medicine, Göttingen, Germany

Tobias Brügmann, University of Bonn, Germany

Herbert Himmel, Bayer, Wuppertal, Germany

Dan Klærke, University of Copenhagen


More information and the agenda will follow soon.

Click here to read the booklet of the 7th User Meeting in 2016.



The event is free. If you are interested to attend register here.

Download here the flyer for information on recommended hotels and public transportation to the headquarters.

(Please note spaces are limited and Nanion reserves the right to give preference to existing clients.)


Posters and oral presentations:

As last year, we are organising a symposium and a poster session. If you are interested to present your data, please send an e-mail with your title and abstract to: This email address is being protected from spambots. You need JavaScript enabled to view it.